These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11190365)

  • 1. Urinary retention with reboxetine-fluoxetine combination in a young man.
    Benazzi F
    Can J Psychiatry; 2000 Dec; 45(10):936. PubMed ID: 11190365
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
    Kasper S
    Psychopharmacology (Berl); 2002 Feb; 159(4):445-6. PubMed ID: 11823898
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
    Clayton AH; Zajecka J; Ferguson JM; Filipiak-Reisner JK; Brown MT; Schwartz GE
    Int Clin Psychopharmacol; 2003 May; 18(3):151-6. PubMed ID: 12702894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
    Künzel HE; Schuld A; Pollmächer T
    Pharmacopsychiatry; 2004 Nov; 37(6):307-8. PubMed ID: 15551201
    [No Abstract]   [Full Text] [Related]  

  • 6. Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine.
    Cooper-Kazaz R; Cohen A; Lerer B
    J Clin Psychopharmacol; 2010 Apr; 30(2):211-2. PubMed ID: 20520303
    [No Abstract]   [Full Text] [Related]  

  • 7. Doxazosin for reboxetine-induced urinary hesitancy.
    Szabadi E
    Br J Psychiatry; 1998 Nov; 173():441-2. PubMed ID: 9926068
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
    Yucel A; Yucel N; Ozcan H; Gulec M; Aydin A
    J Clin Psychopharmacol; 2015 Jun; 35(3):354-5. PubMed ID: 25822478
    [No Abstract]   [Full Text] [Related]  

  • 9. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
    Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine in the treatment of cyclic mood disorders.
    Brodsky L
    Psychiatr J Univ Ott; 1990 Nov; 15(4):237. PubMed ID: 2284378
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial.
    Prospero-Garcia KA; Torres-Ruiz A; Ramirez-Bermudez J; Velazquez-Moctezuma J; Arana-Lechuga Y; Teran-Perez G
    J Clin Psychiatry; 2006 Nov; 67(11):1820. PubMed ID: 17196069
    [No Abstract]   [Full Text] [Related]  

  • 12. Urinary retention with fluoxetine-haloperidol combination in a young patient.
    Benazzi F
    Can J Psychiatry; 1996 Nov; 41(9):606-7. PubMed ID: 8946091
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin.
    Kasper S; Wolf R
    Eur Neuropsychopharmacol; 2002 Apr; 12(2):119-22. PubMed ID: 11872327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine and treatment-refractory elderly patients with depression.
    Chue P
    Can J Psychiatry; 2000 Sep; 45(7):669. PubMed ID: 11056834
    [No Abstract]   [Full Text] [Related]  

  • 15. Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.
    Sivrioglu EY; Topaloglu VC; Sarandol A; Akkaya C; Eker SS; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):548-50. PubMed ID: 17123681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymptomatic reboxetine overdose.
    Bandinelli PL; Polselli GM
    Int J Neuropsychopharmacol; 2006 Apr; 9(2):257. PubMed ID: 15967062
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
    Jazayeri S; Tehrani-Doost M; Keshavarz SA; Hosseini M; Djazayery A; Amini H; Jalali M; Peet M
    Aust N Z J Psychiatry; 2008 Mar; 42(3):192-8. PubMed ID: 18247193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible adverse drug interactions between fluoxetine and other psychotropics.
    Lock JD; Gwirtsman HE; Targ EF
    J Clin Psychopharmacol; 1990 Oct; 10(5):383-4. PubMed ID: 2258459
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.